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Abstract
Background: Body mass index (BMI) is largely investigated as a prognostic and predictive factor in triple-negative
breast cancer (TNBC). Overweight and obesity are linked to a variety of pathways regulating tumor-promoting
functions, including the DNA damage response (DDR). The DDR physiologically safeguards genome integrity but, in
a neoplastic background, it is aberrantly engaged and protects cancer cells from chemotherapy. We herein verified
the role of BMI on a previously assessed association between DDR biomarkers and pathological complete response
(pCR) in TNBC patients treated with neoadjuvant chemotherapy (NACT).
Methods: In this retrospective analysis 54 TNBC patients treated with NACT were included. The relationship between
DDR biomarkers, namely phosphorylated H2A Histone Family Member X (γ-H2AX) and phosphorylated checkpoint
kinase 1 (pChk1), and pCR was reconsidered in light of BMI data. The Pearson’s Chi-squared test of independence
(2-tailed) and the Fisher Exact test were employed to assess the relationship between clinical-molecular variables and
pCR. Uni- and multivariate logistic regression models were used to identify variables impacting pCR. Internal validation
was carried out.
Results: We observed a significant association between elevated levels of the two DDR biomarkers and pCR in patients
with BMI < 25 (p = 0.009 and p = 0.022 for γ-H2AX and pChk1, respectively), but not in their heavier counterpart. Results
regarding γ-H2AX were confirmed in uni- and multivariate models and, again, for leaner patients only (γ-H2AXhigh vs
γ-H2AXlow: OR 10.83, 95% CI: 1.79–65.55, p = 0.009). The consistency of this finding was confirmed upon internal
validation.
Conclusions: The predictive significance of γ-H2AX varies according to BMI status. Indeed, elevated levels of γ-H2AX
seemed associated with lower pCR rate only in leaner patients, whereas differences in pCR rate according to γ-H2AX
levels were not appreciable in heavier patients. Larger investigations are warranted concerning the potential role of
BMI as effect modifier of the relationship between DDR-related biomarkers and clinical outcomes in TNBC.
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Background
Overwhelming evidence connects obesity with breast can-
cer (BC) [1, 2]. In particular, obesity is increasingly desig-
nated as a risk factor for triple-negative BC (TNBC) [3–8].
Preclinical models have provided ground for the role
of cellular metabolism and energy balance in affecting
cancer progression and, ultimately, therapeutic out-
comes [9]. The hormonal milieu underling obesity is
complex. In obese patients, the altered dynamics of insu-
lin secretion translates into increased levels of insulin
and insulin-like growth factors. In addition, abnormal-
ities have been described in the expression profiles of
various adipokines and cytokines [9]. This abnormal
status leads to the activation of oncogenic intracellular
molecular networks in cancer cells, such as the JAK2/
STAT3, MAPK/ERK, PI3K/AKT and NF-kB pathways
[9]. Moreover, the low chronic tissue inflammation sta-
tus that accompanies obesity enhances the activity of
some factors, such as hypoxia-inducible factor 1α
(HIF1α), which in turn promotes angiogenesis and
acquisition of cancer stem-like traits [10–12].
Next, obesity-related oxidative stress generates reactive
oxygen species (ROS), which may outcompete the antioxi-
dant defense systems, thus altering the structure of the
DNA and ultimately leading to damages and mutations
[13]. In order to deal with endogenous and exogenous
sources of DNA damage, preventing the onset and accu-
mulation of sub-lethal genetic lesions, and avoiding lesion
amplification upon cellular division, eukaryotic cells are
equipped with a tightly regulated machinery, the DNA
damage response (DDR) pathway [14]. Through the coor-
dinated recruitment of cell cycle checkpoints, DNA repair
mechanisms and apoptotic pathways, the DDR orches-
trates repair of DNA lesions, or promote self-elimination
of cells whose damages overwhelm repair capacity [14].
In a neoplastic background, the DDR apparatus is ab-
errantly regulated. Oncogene-induced replication stress
and altered cell cycle progression, arising from muta-
tional events in proliferative and cell-cycle control genes,
respectively, require an adaptive response to ensure cell
viability [15]. In this frame, activation of the Ataxia-
Telangiectasia Mutated (ATM)-Checkpoint Kinase 2
(Chk2) and ataxia telangiectasia and Rad3-related pro-
tein (ATR)-Checkpoint kinase 1 (Chk1) pathways
becomes central [16]. One of the most dramatic implica-
tion of the increased ability of cancer cells to correct
genetic lesions when exposed to DNA-damaging agents
refers to resistance to chemotherapy [17]. Consistently,
DNA damage-related biomarkers are the focus of
intense investigations for the development of predictive
tools, and great expectations are placed on novel drugs
able to interfere with DNA repair ability [15].
We have recently reported on the association between
elevated levels of phosphorylated H2A Histone Family
Member X (γ-H2AX), a marker of DNA double-strand
breaks that activate the ATM-Chk2 pathway, and
reduced pathological complete response (pCR) rate in
TNBC patients treated with neoadjuvant chemotherapy
(NACT) [18]. In this cohort, we did not observe a
significant association between phosphorylated Chk1
levels and the explored outcome [18].
Given the connection between obesity and TNBC, and
the link between oxidative stress and the DDR at the
molecular level (Fig. 1), we herein investigated the
Fig. 1 Schematic representation of the relationship between obesity-related alterations and the DDR machinery. The increased production of
reactive oxygen species (ROS), stemming from both metabolic reprogramming of cancer cells and the obesity-related inflammatory status (left),
results in elevated levels of DNA damage (oxidative stress-related DNA damage) with the consequent activation of the ATM and ATR pathways.
Moreover, insulin, whose levels increase in obese patients (insulin resistance), activates ATM that in turn increases glucose uptake via AKT (right)
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impact of body mass index (BMI), a widely used indica-
tor of generalized obesity, on the association between
DDR biomarkers and pCR.
Methods
From the original series of 66 TNBC patients treated
with NACT analyzed for studying the predictive signifi-
cance of γ-H2AX and pChk1 [18], we were able to re-
trieve BMI data for 54 patients. For this retrospective
analysis, patients were considered eligible if all the rele-
vant clinical-molecular information were available, and if
the presurgical treatment was completed. Regarding es-
trogen receptor (ER) and progesterone receptor (PgR),
six tumors displayed a weak (≤10%) expression of either
ER or PgR in diagnostic biopsies, which became negative
(0%) in surgical samples after treatment. These patients
were included on the basis of the clinical plausibility of a
basal-like portrait of their tumors [19]. BMI was defined
using the cutoff suggested by the world health
organization (WHO) to distinguish between normal
weight (BMI <25) and overweight (BMI ≥25) subjects.
NACT consisted in concomitant or sequential
anthracycline-taxane-based regimens, as detailed
elsewhere [18]. pCR was defined as no residual invasive
tumor in both breast and axilla, irrespective of the pres-
ence of ductal carcinoma in situ (ypT0/is ypN0). The
immunohistochemical assessment of γ-H2AX and
pChk1 was performed in formalin-fixed paraffin-
embedded (FPPE) tissues with the anti-phospho-H2AX
(Ser139) (clone JBW301) mouse monoclonal antibody
(MAb) (Upstate) and the anti-phospho-Chk1 (Ser345)
(clone 133D3) rabbit MAb (Cell Signaling) [18]. The ex-
pression levels of γ-H2AX were evaluated in terms of
nuclear-expressing tumor cells and analyzed as a cat-
egorical variable. To this end, the median score of all tu-
mors was used to classify low and high expressing
samples (γ-H2AX low and γ-H2AX high) [18]. pChk1 was
considered as positive or negative on the basis of nuclear
staining intensity (0: negative, 1+: weak, 2+: moderate, 3
+: strong). Tumors with absent (0) nuclear staining were
considered as negative (pChk1neg), and tumors with
weak to strong (1–3) nuclear staining were considered
as positive (pChk1pos) [18]. Immunoreactivity was
assessed by two independent investigators (ADB and
CE) and discordant cases were reviewed by a third
expert (MM). This retrospective study was conducted in
accordance with the Declaration of Helsinki and was
approved by the Ethic Committee of “Regina Elena”
National Cancer Institute, the coordinating centre. Written
informed consents were secured before chemotherapy.
Statistical analysis
Descriptive statistics were computed for all the variables
of interest including clinical, pathological, molecular and
anthropometric features. To assess the relationship
between categorical variables we used the Pearson’s
Chi-squared test of independence (2-tailed) and the
Fisher Exact test, depending upon the size of groups
compared. BMI was computed as weight in kilograms
divided by the square of height in meters (kg/m2), and
considered as a categorical variable on the basis of the
cutoff proposed by the WHO to define normal weight
(BMI < 25) and overweight (≥25) patients. Univariate
logistic regression model was used to identify variables
impacting pCR. A multivariate logistic regression model
was built using a stepwise regression approach (forward
selection) and the related estimates reported as Odds
Ratio (OR) and 95% Confident Interval (CI). The enter
and remove limits were p = 0.10 and p = 0.15, respect-
ively. A multivariate logistic regression model was also
generated by including all the variables significant at the
univariate assessment. To estimate the risk of an over-
fitted model, internal validation was performed using a
re-sampling without replacement procedure [20, 21].
One hundred datasets were generated by randomly
removing approximately 20% of the original sample and
the replication rate was calculated. We considered statis-
tically significant p values less than 0.05. Statistical
analyses were carried out using SPSS software (SPSS
version 21, SPSS Inc., Chicago, IL, USA).
Results
Cancer- and patient-related features are summarized in
Table 1. In this series of 54 TNBC patients, 31 (57.4%)
patients had a BMI < 25. With the exception of an asso-
ciation between BMI < 25 and younger age at diagnosis,
we did not observe any further relationship between
BMI and clinical-molecular features, DDR biomarkers
and pCR (Table 2). Likewise, neither γ-H2AX nor pChk1
were associated with clinical-molecular features (data
available upon request).
Although the sample size was slightly smaller
compared with the original cohort [18], consistently with
our previous results, elevated γ-H2AX levels retained
significant association with reduced pCR rate (p = 0.015),
and a suggestion towards an association between pChk1
and pCR was also observed (p = 0.057) (data available
upon request).
When stratifying by BMI, the association between
DNA damage biomarkers and pCR was not appreciable
in patients with BMI ≥ 25 (Table 3). Conversely, in leaner
patients, namely patients with a BMI < 25, elevated levels
of γ-H2AX and pChk1 predicted lower pCR rate
(Table 3). Uni- and multivariate analyses confirmed the
predictive ability of γ-H2AX in leaner patients (γ-
H2AXhigh vs γ-H2AXlow: OR 10.83, 95% CI: 1.79–65.55,
p = 0.009), but not in patients with BMI ≥25 (Table 4).
The replication rate of the model in leaner patients was
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87%. This data indicates that the association between
higher levels of γ-H2AX and lower pCR rate tested sig-
nificant in 87 out of 100 replications. In the multivariate
model adjusted by variables testing significant at univari-
ate assessment, the association between γ-H2AX and
pCR was borderline significant in patients with BMI < 25
(Table 5).
Discussion
The aim of the present study was to assess the role of
BMI on the previously verified association between
DDR biomarkers and pCR rate in a historic cohort of
TNBC patients treated with NACT. We observed a
significant association between elevated levels of
γ-H2AX and reduced pCR rate in leaner patients. A
similar suggestion was observed for pChk1, albeit at a
not fully significant extent.
The achievement of pCR in TNBC is an extremely
relevant clinical goal, considering that this intermediate
endpoint is tied to long-term survival outcomes. In this
view, the search for biomarkers foreseeing sensitivity/re-
sistance to NACT is of paramount importance [22, 23].
Table 1 Baseline characteristics and treatment outcome of
TNBC patients treated with neoadjuvant chemotherapy (N = 54)
Age at diagnosis
median (min-max) [IQrange] 49.2 (26.7–76.6) [45.3–60.3]
<49 25 (46.3)
≥49 29 (53.7)
Stage
II 18 (33.3)
III 36 (66.7)
Grade
1–2 22 (40.7)
3 32 (59.3)
Ki-67
median (min-max) [IQrange] 70.0 (10.0–90.0) [43.7–80.0]
Chemotherapy
Sequential 47 (87.0)
Concomitant 7 (13.0)
pCR
No 37 (68.5)
Yes 17 (31.5)
BMI
median (min-max) [IQrange] 23.9 (17.5–41.6) [21.7–25.9]
< 25 31 (57.4)
≥ 25 23 (42.6)
γ-H2AX
Low 25 (46.3)
High 29 (53.7)
pChk1
Neg 16 (29.6)
Pos 38 (70.4)
Table 2 Association between BMI and clinical-molecular features
(N = 54)
BMI Chi2 Test
<25 ≥25 p-value
N (%) N (%)
Age at diagnosis
< 49 20 (80.0) 5 (20.0) 0.002
≥ 49 11 (37.9) 18 (62.1)
Stage
II 12 (66.7) 6 (33.3) 0.331
III 19 (52.8) 17 (47.2)
Grade
1–2 13 (59.1) 9 (40.9) 0.836
3 18 (56.3) 14 (43.8)
Ki-67
Low 15 (60.0) 10 (40.0) 0.721
High 16 (55.2) 13 (44.8)
Chemotherapy
Sequential 27 (57.4) 20 (42.6) 0.999a
Concomitant 4 (57.1) 3 (42.9)
pCR
No 19 (51.4) 18 (48.6) 0.184
Yes 12 (70.6) 5 (29.4)
γ-H2AX
Low 16 (64.0) 9 (36.0) 0.363
High 15 (51.7) 14 (48.3)
pChk1
Neg 12 (75.0) 4 (25.0) 0.090
Pos 19 (50.0) 19 (50.0)
aFisher’s Exact Test
Table 3 Association between DDR biomarkers and pCR in TNBC
patients with BMI < 25 and BMI ≥ 25 (N = 54)
BMI < 25 BMI≥ 25
No pCR pCR Fisher’s
Exact Test
No pCR pCR Fisher’s
Exact Test
N (%) N (%) p-value N (%) N (%) p-value
pCHK1
Neg 4 (33.3) 8 (66.7) 0.022 4 (100.0) 0 (0.0) 0.539
Pos 15 (78.9) 4 (21.1) 14 (73.7) 5 (26.3)
γ-H2AX
low 6 (37.5) 10 (62.5) 0.009 7 (77.8) 2 (22.2) 0.999
high 13 (86.7) 2 (13.3) 11 (78.6) 3 (21.4)
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Over time, a variety of potential DDR-related biomarkers
have been proposed, with inconsistent results. However,
in previous studies the focus was mostly placed on single
endpoints acting in the context of distal DDR effectors,
such as the excision repair cross-complementation
group1 (ERCC1) protein [24, 25]. Coherently with our
preclinical findings describing Chk1 as a crucial medi-
ator of chemotherapy resistance in patient-derived CSC
models and xenografts [26], we decided to investigate
key DDR pathway components deputed to initiate cell
cycle arrest upon DNA damage.
The use of a retrospective study design, particularly in
a moderately-sized cohort, invites caution in results
interpretation. Nevertheless, these findings hold a poten-
tial in generating hypotheses on how the host metabolic
status may be linked to specific cancer-related functions
and therapeutic outcomes. Thus, our results provided
ground for preclinical studies addressing the connection
between specific metabolic pathways, and obesity-related
molecular changes, and the biology of TNBC.
As briefly aforementioned, anthropometric features
and particularly BMI, have been the focus of consider-
able attention in TNBC. Nevertheless, conflicting results
were reported when BMI was analyzed as a potential
prognostic factor. Tait et al. did not observe any effect of
BMI and diabetes on survival outcomes [27], whereas
Hao et al. [28] and Cakar et al. [29] observed that over-
weight is associated with adverse outcomes in TNBC,
consistently with the findings reported by Widschwend-
ter in the case of severe obesity (BMI ≥ 40) [30]. Regard-
ing the association between BMI and pCR, a pooled
analysis including patients from eight neoadjuvant trials
verified the detrimental effect of overweight and obesity
on survival outcomes, but not on pCR, in TNBC.
Table 4 Uni- and multivariate logistic regression models of
patient- and disease-related features and pathological complete
response (N = 54)
BMI < 25
Univariate logistic
regression
Multivariate logistic
regressiona
OR 95%CI p-value OR 95%CI p-value
Stage
III vs II 0.37 0.08–1.81 0.220
Grade
3 vs 1–2 0.98 0.23–4.25 0.981
Ki-67
High vs Low 0.19 0.04–0.97 0.046
γ-H2AX
High vs Low 10.83 1.79–65.55 0.009 10.83 1.79–65.55 0.009
pChk1
Pos vs Neg 7.50 1.47–38.28 0.015
BMI≥ 25
Univariate logistic
regression
Multivariate logistic
regression
OR 95%CI p-value OR 95%CI p-value
Stage
III vs II 0.65 0.06–7.32 0.727
Grade
3 vs 1–2 3.00 0.39–23.07 0.291
Ki-67
High vs Low 0.25 0.02–2.70 0.253
γ-H2AX
High vs Low 1.05 0.14–7.93 0.964
pChk1
Pos vs Neg Not applicable
awith forward stepwise inclusion
Table 5 Uni- and multivariate logistic regression models of
patient- and disease-related features and pCR upon adjustment
of the multivariate model for Ki-67, γ-H2AX and pChk1 (N = 54)
BMI < 25
Univariate logistic
regression
Multivariate logistic
regressiona
OR 95%CI p-value OR 95%CI p-value
Stage
III vs II 0.37 0.08–1.81 0.220
Grade
3 vs 1–2 0.98 0.23–4.25 0.981
Ki67
High vs Low 0.19 0.04–0.97 0.046 0.30 0.04–2.06 0.223
γ-H2AX
High vs Low 10.83 1.79–65.55 0.009 6.34 0.89–45.33 0.066
pChk1
Pos vs Neg 7.50 1.47–38.28 0.015 4.82 0.77–30.26 0.093
BMI≥ 25
Univariate logistic
regression
Multivariate logistic
regression
OR 95%CI p-value OR 95%CI p-value
Stage
III vs II 0.65 0.06–7.32 0.727
Grade
3 vs 1–2 3.00 0.39–23.07 0.291
Ki-67
High vs Low 0.25 0.02–2.70 0.253
γ-H2AX
High vs Low 1.05 0.14–7.93 0.964
pChk1
Pos vs Neg Not applicable
aAdjusted for: Ki-67, γ-H2AX and pChk1
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However, when considering the overall study population
(8872 patients), BMI significantly impacted both pCR and
survival [31]. Overall, data on BMI and metabolic determi-
nants as predictive/prognostic factors in TNBC are still in
their infancy. To this end, our data add an important piece
to the puzzle, suggesting that DNA repair proficiency of
TNBC cells may vary in relation to metabolic cues. Our
data seem to indicate the existence of an inverse associ-
ation between elevated levels of γ-H2AX and reduced
pCR rate in leaner patients only. Study weaknesses mainly
stemming from the quite restricted sample size and study
design, i.e., retrospective case series, refrained us from
conducting subgroup analysis within each BMI category.
In future and adequately sized studies, informative details
may come from characterizing the distribution of TNBC
molecular subtypes across BMI strata along with a more
extensive definition of the metabolic profile of the host. In
more details, two strategies should be pursued in our
opinion. First, TNBC is a heterogeneous disease [32].
Gene expression profiles revealed the existence of multiple
molecular entities [32]. For instance, a luminal androgen
receptor (LAR) subtype was identified and characterized
for the enrichment of hormonally regulated pathways,
such as those involved in steroid synthesis and androgen/
estrogen metabolism. Consistently, a great interest sur-
rounds the use of antiandrogens in TNBC expressing the
androgen receptor, and preliminary clinical data support
the therapeutic relevance of androgen receptor targeting
in this disease [33]. Conversely, the basal-like 1 subtype is
characterized by the expression of DNA damage response
pathways, together with genes associated with prolifera-
tion and cell cycle checkpoints [32]. On this basis, we can
speculate that the host metabolic status might have a dif-
ferent significance across the constellation of TNBC sub-
types, and that metabolic avenues might specifically be
linked to some TNBC subtype, without transversally influ-
encing all the disease entities encompassed into the defin-
ition of TNBC. If this is the case, the different “metabolic
dependency” of various TNBC subtypes may, at least
partly, account for the effect of BMI on the predictive
ability of DDR biomarkers reported in the present study.
Second, dissecting the link between metabolic
abnormalities, specific molecular pathways, and clinical
outcomes based on the exclusive consideration of BMI
probably might represent an oversimplification. Accord-
ingly, we have implemented our research agenda on meta-
bolic factors in BC [34–37], which now includes a deeper
characterization of the metabolic status in patients whose
tumors will be evaluated for candidate molecular
biomarkers. The molecular analysis of pathways poten-
tially connected with therapeutic resistance will be
integrated by an extensive metabolic characterization,
which includes: i) prospective collection of anthropomet-
ric data using standardized operative procedures (SODs)
and inclusion of waist circumference, which is more
tightly related to visceral adiposity and more strongly as-
sociated with multiple chronic diseases by underlying
metabolic alterations [38], ii) dual-energy X-ray absorpti-
ometry (DEXA) to calculate the percent of body fat in the
visceral and subcutaneous compartments, iii) homeostatic
model assessment (HOMA) index for assessing insulin
resistance, and iv) fasting glucose, insulin levels and lipidic
profile including total and fractionated cholesterol. The
combination of information collected both at the tissue
and systemic level will help depict a more comprehensive
scenario on the influence of metabolic determinants on
TNBC, and will thus possibly represent the starting point
for larger, prospective studies.
Conclusions
The predictive ability of DDR biomarkers in TNBC pa-
tients who received NACT seems to be significantly af-
fected by BMI, with the highest predictive performance
of the biomarkers of interest being achieved for patients
with BMI < 25. Based on the promising nature of these
results, future translational studies within this pipeline
may be greatly implemented by the prospective and
standardized collection of anthropometrics including
BMI, a widely accepted indicator of general adiposity,
along with waist circumference, which better captures
visceral adiposity. Anthropometric data will be efficiently
integrated by circulating biomarkers of energy metabol-
ism. In addition, the metabolic study may be further and
easily enriched by DEXA scans for body composition.
The systematic evaluation of the metabolic asset of the
host will be then weighted against the molecular portrait
of the specific molecular subtypes of TNBC. As a likely
result, the combination of metabolic and molecular
pieces will display an entirely renewed puzzle which will
help address the clinical significance of deregulated
pathway nodes, especially when they are potentially af-
fected by the metabolic milieu of the patients. In conclu-
sion, larger studies, envisioning the molecular
characterization of TNBC coupled with an extensive as-
sessment of the host metabolic status, are warranted to
provide novel insights into this fascinating topic.
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